Crawley

Researchers are evaluating the effects of NNC0487-0111 in adults with excess body weight and obstructive sleep apnea who are not using positive airway pressure treatment. This Phase 3 trial aims to assess the safety and effectiveness of this medication in helping participants lose weight and improve their sleep apnea. The study compares NNC0487-0111 with a placebo, which is an inactive treatment given by chance to participants. Participants receive weekly injections of either NNC0487-0111 or a matching placebo under the skin using pre-filled pen injectors applied to the thigh, abdomen, or upper arm. Both groups follow a reduced-calorie diet and increase physical activity during the study. The treatment period lasts for 80 weeks, during which researchers monitor changes in body weight and sleep apnea severity. Throughout the study, participants undergo regular assessments including body weight measurements and evaluation of the apnea-hypopnea index AHI to track sleep apnea severity. Additional tests measure sleep-related impairment, blood pressure, cholesterol levels, and blood sugar control. Safety is monitored by tracking any adverse events during the 84 weeks of the study. Participants progress is carefully followed to understand the impact of the treatment on weight and sleep apnea over time.

Researchers are evaluating the effectiveness and safety of NNC0487-0111 in adults with overweight or obesity who also have obstructive sleep apnoea and are being treated with positive airway pressure. This phase 3 study compares NNC0487-0111 to a placebo, which contains no active medicine, to see how well the treatment helps with weight loss and improvement in sleep apnoea symptoms. Participants will receive one of two dose levels of NNC0487-0111 or a matching placebo as weekly injections under the skin. These injections are given alongside a reduced-calorie diet and increased physical activity. The treatment is administered using pre-filled pen injectors to the thigh, abdomen, or upper arm, and the study lasts for 80 weeks. Throughout the trial, participants will be monitored regularly to assess changes in body weight, sleep apnoea severity measured by the apnoea-hypopnoea index AHI, and other health measures such as waist and neck circumference, blood pressure, cholesterol, blood sugar, and sleep quality scores. Safety is tracked by recording any treatment-related adverse events. The study runs until week 80, with follow-up continuing through week 84 to evaluate ongoing safety and effectiveness.

Researchers are testing a new medicine called SNV1521 for people with advanced or metastatic solid tumors. The study aims to find out if SNV1521 is safe, well-tolerated, and effective in treating these cancers. This phase 1 trial also explores different doses of SNV1521 to determine the most effective and safe dosage, as well as its potential use in combination with other cancer therapies. Participants will receive SNV1521 as an oral tablet with the dose and frequency depending on the treatment group. The study includes several experimental arms such as monotherapy dose escalation and expansion, combination dose escalation, and specific dose expansions for various cancers including prostate, pancreatic, breast, ovarian, and solid tumors with brain metastases. Other drugs like DB-1310 infusion, Abiraterone, and Darolutamide oral are also involved depending on the treatment arm. During the study, participants will be monitored closely for safety and tolerability, including checking for dose-limiting toxicities during the first 28-day treatment cycle and ongoing safety assessments up to 13 months from the first dose. Researchers will evaluate disease status using measurable criteria and assess overall health and performance status. The trial runs through December 2027, with participants undergoing regular evaluations to measure the effects and side effects of the treatments.